Lonza (SWX:LONN) announced today that it has received the Frost & Sullivan Market Leadership Award for Global Transfection Leadership. This award is given to a single company annually that has displayed excellence in all areas of the market leadership process, including the identification of market challenges, drivers and restraints, as well as strategy development, and methods of addressing these market dynamics.
To determine the recipient of this award, Frost & Sullivan compares competitors and ranks each for relative position via interviews with market participants and extensive secondary research of proprietary data sources. Frost & Sullivan then presents the prestigious award to the company that received the number one industry rank.
"The Nucleofector® Technology is the first of its kind in being the only non-viral method for highly efficient transfection of hard-to-transfect cell lines and primary cells or stem cells. This product has addressed the key drawbacks in cell delivery technology, which have proven to be substantial barriers in the growth and development of the global transfection market", explains Swetha Shantikumar, Frost & Sullivan Research Analyst in the Drug Discovery Technologies Group.
“We are honored for being acknowledged for our efforts in developing a comprehensive product portfolio of Life Science research tools around cultured cells, including transfection.”, appreciates Teun van der Heide, Head of Research Solutions in Lonza’s Bioscience business. “Lonza is running one of the largest R&D groups working on gene transfer, isolation, and culture of primary cells. We believe that cell-based research solutions, especially complete solutions employing primary cultured cells, will play a crucial role for future discoveries in Life Science research and Drug Discovery”.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. At the site in Cologne, Lonza develops and commercializes non-viral gene transfer products for primary cells and difficult-to-transfect cell lines. These cells are important model systems for both basic and clinical research as they more accurately reflect the condition and behavior of cells within an organism when compared to commonly used laboratory cell lines. With the specially developed Amaxa® Nucleofector® Technology, the functionality of different genes can now be analyzed in biologically relevant cell types. These results are used to more efficiently identify new targets for pharmaceuticals and therapies.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.94 billion. Further information can be found at www.lonza.com.
For further Information:
Lonza Group Ltd:
Phone +41 61 316 8798
Lonza Cologne AG:
Marketing Communication and Product PR
Phone: +49 221 99199 464